Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer

Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG

FDA Approves Alhemo: A Breakthrough Once-Daily Treatment for Hemophilia A and B with Inhibitors

Alhemo, FDA approval, hemophilia A, hemophilia B, inhibitors, concizumab, once-daily treatment, subcutaneous injection, prophylactic treatment

Sarepta Therapeutics Halts Development of Vesleteplirsen, a Next-Generation Exon-Skipping Therapy for Duchenne Muscular Dystrophy

Sarepta Therapeutics, Vesleteplirsen (SRP-5051), Duchenne Muscular Dystrophy (DMD), Exon-Skipping Therapy, FDA Feedback, Therapeutic Landscape